PhaseBio Pharmaceuticals (PHAS) Short Interest Ratio & Short Volume

Short interest is the volume of PhaseBio Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 15th, investors have sold 2,070,000 shares of PHAS short. 5.37% of PhaseBio Pharmaceuticals' shares are currently sold short. Learn More on PhaseBio Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PHAS shares currently have a short interest ratio of 3.0. Learn More on PhaseBio Pharmaceuticals's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.37% of PhaseBio Pharmaceuticals' floating shares are currently sold short.

PhaseBio Pharmaceuticals saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 2,070,000 shares, an increase of 31.0% from the previous total of 1,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

PhaseBio Pharmaceuticals currently has issued a total of 49,858,000 shares. Some of PhaseBio Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. PhaseBio Pharmaceuticals currently has a public float of 38,520,000 shares.

5.37% of PhaseBio Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to PhaseBio Pharmaceuticals: GeoVax Labs, Inc. (0.31%), Revelation Biosciences, Inc. (8.34%), Virpax Pharmaceuticals, Inc. (3.42%), Mustang Bio, Inc. (2.35%), Evoke Pharma, Inc. (0.78%), Phio Pharmaceuticals Corp. (0.47%), Atreca, Inc. (0.37%), Aravive, Inc. (1.81%), 60 Degrees Pharmaceuticals, Inc. (0.75%), Ensysce Biosciences, Inc. (0.60%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($3.48 billion), Charter Communications, Inc. ($2.85 billion), Twitter, Inc. ($1.89 billion), T. Rowe Price Group, Inc. ($1.78 billion), Coinbase Global, Inc. ($1.77 billion), PG&E Co. ($1.75 billion), Lucid Group, Inc. ($1.58 billion), Rivian Automotive, Inc. ($1.42 billion), Roblox Co. ($1.39 billion), and Williams-Sonoma, Inc. ($1.33 billion). View all of the most shorted stocks.

Short selling PHAS is an investing strategy that aims to generate trading profit from PhaseBio Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for PhaseBio Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PHAS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PHAS, twice per month. The most recent reporting period available is October, 15 2022.